AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $23M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$23M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 10 added, 1 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $176.78
- 52-wk high
- $183.51
- High
- $180.90
- 52-wk low
- $60.45
- Low
- $174.54
- Prev close
- $177.73
- Mkt cap
- $23.85B
- Volume
- 1.66M
- Beta
- 1.58
- P/S
- 20.2x
- P/B
- 55.7x
- Profit margin
- -38.3%
- Op margin
- -38.3%
- ROE
- -4584.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about GH filings
Are insiders buying or selling Guardant Health Inc (GH) stock?
Net selling: insiders sold $23M and bought $0 of GH stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $202K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Freeman, Chris (Chief Commercial Officer), who sold $10.8M. The latest filing was on Sep 17, 2026.
Which members of Congress have traded GH recently?
None. No member of Congress disclosed a GH trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this GH smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- MI
Millennium
$158.3M
added
- DS
D.E. Shaw
$148.9M
added
- CI
Citadel
$145.8M
added
What insiders are doing
What Congress is doing
Buys (1)
How top traders are positioned
No tracked top-trader positions in GH right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 20.3% below what analysts expected.
Earnings per share
-$0.74 expected
Revenue
No comparable estimate
Company adjusted EPS
From the company's release
Compared on the analyst basis, which counts earnings differently from the company.
FY2026 guidance
$1.34B to $1.36B
No comparable estimate
Reports Nov 4, 2026, in 34 days
Estimates as of Sep 30, 2026
EPS expected
-$0.39 to -$0.22
Revenue expected
21 analysts
Last 30 days
Split both ways
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $265.2M | $281.3M | $301.7M | $335.0M |
| Cost of what it sold | $93.6M | $99.5M | $104.9M | $115.9M |
| Gross profit | $171.6M | $181.8M | $196.7M | $219.0M |
| What it spent | ||||
| Research and development | $90.0M | $98.3M | $91.0M | $96.5M |
| Sales and admin | $53.3M | $60.9M | $57.9M | $61.7M |
| Other operating costs | $127.4M | $143.4M | $169.1M | $190.0M |
| Total operating expenses | $270.6M | $302.6M | $318.1M | $348.1M |
| What was left | ||||
| Operating profit | -$99.0M | -$120.8M | -$121.3M | -$129.1M |
| Interest on debt | $943.0K | $1.2M | $1.3M | $1.3M |
| Profit before tax | -$92.6M | -$130.2M | -$111.7M | -$120.0M |
| Tax | $136.0K | -$1.7M | $372.0K | $185.0K |
| Net profit | -$92.7M | -$128.5M | -$112.1M | -$120.1M |
| EBITDA | -$82.2M | -$119.0M | -$100.9M | -$109.0M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Guardant Health (GH) Stock Could Be Undervalued Despite Its 5x Run
Leans bullishSep 27Guardant Health (GH) Rides Liquid Biopsy Growth Narrative With Valuation Still In Focus
Leans bullishSep 25How FDA Approval Has Changed The Investment Story At Guardant Health Stock
BullishSep 23Form 4 Guardant Health Inc For: 22 September By Investing.com
NeutralSep 22Form 4 Guardant Health Inc For: 22 September By Investing.com
NeutralSep 22Guardant Health, Inc. (GH) Stock Analysis: A Strong Buy With 9% Upside Potential
BullishSep 21Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
BullishSep 19Cathie Wood’s ARK increases stake in Guardant Health stock
NeutralSep 17
Macro
20 macro signals shaping GH right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results